{"disease":{"id":"rare-tumors","name":"rare tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07524114","title":"Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT07489378","title":"NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07307053","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04482309","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":477,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05046444","title":"Solving Riddles Through Sequencing","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Munich Leukemia Laboratory","has_results":false},{"nct_id":"NCT01802567","title":"Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Giselle Sholler","has_results":true},{"nct_id":"NCT05868629","title":"Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06804655","title":"Pharmacoscopy for Patients With Refractory Primary Brain Tumors","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"University of Zurich","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}